Alaunos Therapeutics reported preclinical data from diet-induced obesity mouse studies showing that ALN1003, their oral metabolic drug candidate, improved insulin-resistance biomarkers, adipose tissue signaling, and liver histology related to metabolic syndrome. The drug lowered fasting insulin and HOMA-IR scores, increased beneficial adiponectin levels, and reduced liver fat accumulation in treated animals. These findings suggest ALN1003 may target multiple aspects of metabolic syndrome, including obesity, insulin resistance, and liver disease, supporting further preclinical development. The company plans additional studies to optimize dosing and better understand mechanisms, while noting the data are early and from non-GLP studies with limited sample sizes.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
